Budenofalk国内上市了吗？

Has it been launched domestically? my country was approved for import in November 2001, with specifications of 0.5mg/2ml and 1mg/2ml. However, Budenofalk is not widely sold, so patients are advised to consult their local pharmacies.

Budenofalk is a glucocorticoid with potent partial anti-inflammatory effects. It can enhance the stability of endothelial cells, smooth muscle cells and lysosomal membranes, inhibit immune reactions and reduce antibody synthesis, thereby reducing the release and activity of allergic mediators such as histamine. It can also reduce the enzymatic process triggered by antigen-antibody binding, inhibit the synthesis and release of bronchial contraction substances and reduce the contraction reaction of smooth muscle.

Acute, subacute, and long-term toxicity studies found that the systemic effects of Budenofalk, such as weight loss, lymphatic tissue, and adrenal cortical atrophy, were weaker than or equivalent to other glucocorticoids. After six different experimental test system evaluations, Budenofalk has no mutagenic or carcinogenic effects.

Clinical trial on the safety and effectiveness of treatment: 85 cases of bronchial asthma patients who received treatment were selected and divided into an experimental group of 43 cases and a control group of 42 cases using the random number table method. Patients in the control group were treated with albuterol sulfate, and patients in the experimental group were treated with Budenofalk. After 2 weeks, the treatment effects and incidence of adverse reactions were compared. Results: The treatment effectiveness rate of patients in the experimental group was 95.35%, which was significantly higher than the 69.05% in the control group, and the difference was statistically significant (P=0.05). No serious adverse reactions occurred in the two groups of patients, and the incidence of adverse reactions in the experimental group was significantly lower than that in the control group, and the difference was statistically significant (P=0.05). Conclusion: Budenofalk is effective and safe when used in bronchial asthma.